ST榕泰(600589.SH):興盛化工因質押違約 擬被動減持公司股份
格隆匯1月28日丨ST榕泰(600589.SH)公佈,公司第二大股東揭陽市興盛化工原料有限公司(“興盛化工”)持有公司無限售流通股股份8014萬股,佔公司總股本的11.38%。
興盛化工於2022年1月28日收到海通證券股份有限公司(“海通證券”)的《關於通知進行違約處置信息披露的函》,興盛化工辦理的部分股票質押式回購交易因違約,質權人海通證券將對與興盛化工之間的股票質押式回購交易啟動違約處置程序,擬在公司發佈公吿之日起15個交易日後的任意連續90個自然日內,通過證券交易所以集中競價方式減持股份的總數不超過公司股份總數的百分之一和以大宗交易方式減持股份的總數不超過百分之二。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.